Private equity firm EQT hopes a higher cash offer for Swedish specialty pharma group Karo Pharma than the one it made two months ago will persuade reluctant shareholders in the biotech to now sell their holdings.

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced September through October 2013.